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The optimal surgical treatment of hepatocellular carcinoma on well-compensated cirrhosis is controversial. Advocates of liver
transplantationcitebetterlong-termsurvival,lowerriskofrecurrence,andtheabilityoftransplantationtotreatboththeHCCand
the underlying liver cirrhosis. Transplantation, however, is not universally available to all appropriate-risk candidates because of a
lack of suﬃcient organ donors and in addition suﬀers from the disadvantages of requiring a more complex pre- and postoperative
management associated with risks of inaccessibility, noncompliance, and late complications. Resection, by contrast, is much more
easily and widely available, avoids many of those risks, is by many accounts as eﬀective at achieving similar long-term survival, and
still allows for safe, subsequent liver transplantation in cases of recurrence. Here, arguments are made in favor of resection being
easier, safer, simpler, and comparably eﬀective in the treatment of HCC relative to transplantation, and therefore being the optimal
initial treatment in cases of hepatocellular carcinoma on well-compensated cirrhosis.
1.Introduction
Hepatocellular carcinoma (HCC) is the seventh most com-
mon cancer worldwide, one of the most common causes of
cancerdeathworldwide,anditsincidenceisincreasing[1–3].
The rate of cancer death from primary liver cancer (90% of
which is HCC [4]) in the United States has increased by over
40% in recent decades [2]. Risk factors for the development
of HCC include hepatitis (most commonly hepatitis B virus
(HBV)orhepatitisCvirus(HCV)),steatohepatitis,cirrhosis,
hepatotoxins, and less commonly hereditary diseases such as
hemochromatosis and alpha-1 antitrypsin deﬁciency. HCC
uncommonly arises in healthy liver parenchyma. HBV is the
most common underlying liver disease, and chronic carriers
have a logarithmically increased risk of developing HCC
compared to the general population [4].
2.The Debate
There is currently no consensus regarding the best surgical
treatment for patients with well-compensated cirrhosis and
early HCC within the Milan criteria (a single tumor <5cm
in maximum diameter, or 2-3 tumors each <3cm, without
lymphovascular invasion [5, 6]). While transplantation is
clearly better for patients with severe cirrhosis and early
HCC, and resection is better than transplantation for
resectable but extra-Milan-criteria HCC on mild cirrhosis,
on the middle ground—early HCC with mild cirrhosis—
wages the debate between transplantation and resection.
3. Advantages of LiverTransplantation
The ability to treat with a single intervention not only
the HCC but also the underlying oncogenic liver disease
from which it arose—and by extension, from which other
tumors may arise—is one of the greatest advantages of liver
transplantation over resection. In high-volume centers, liver
transplantation achieves this goal with acceptable morbidity
and mortality (Table 1).
Furthermore, not only is liver transplantation relatively
safe, but compared with resection, it has been reported
to produce a longer 5-year survival and a lower rate of
recurrence (Table 1). The reasons for these improved results
compared to resection are diﬃcult to discern, however, and
may be related to a truly superior extirpation of gross and
microscopic disease or to selection bias, especially as might2 International Journal of Hepatology
Table 1: Series comparing RSX and LT for HCC on cirrhosis.
First author [ref] Year N
RSX
N
LT
Mb (%)
RSX
Mb (%)
LT
Mt (%)
RSX
Mt (%)
LT
Overall
5-YS
RSX
Overall
5-YS
LT
Rec (%)
RSX
Rec (%)
LT
Iwatsukiwi/o [46] 1991 17∗∗ 71∗∗ NR NR NR NR 0% 41% 50 43
Ringewi/o [47] 1991 131∗∗ 61∗∗ NR NR 1530-d,∗ 1530-d,∗ 36% 15% NR NR
Vargaswi [48] 1995 35 11 NR NR NR NR 58%
1-YS
81%
1-YS 40 0
Tanwi/o [49] 1995 12 15 33NR 13NR 8.3NR 6.7NR 33%
3-YS
63%
3-YS 45 15
Michelwi/o [50] 1997 102 113 39NR 38NR 8.8NR 22NR 31% 32% 86 30
Philosophewi/o [51] 1998 67∗∗ 58∗∗ NR NR 4430-d 1330-d 38% 45% 55 20
Colellawi/o [52] 1998 41 55 NR NR NR NR 44% 68% NR NR
MazziottiNR [53] 1998 238 41 42NR 80NR 4.630-d 6.230-d 41% 69% NR NR
Ottowi/o [54] 1998 52 50 NR NR 2130-d 8.030-d 37% 44% 21 8.0
WeimannNR [55] 1999 32 31 NR NR 1330-d 1030-d 34% 63% 19 0
Yamamotowi/o [25] 1999 294 270 NR NR 1.430-d 7.830-d 47% 54% NR NR
Llovetwi [19] 1999 77 87 NR NR 3.990-d 2.390-d 51% 69% 57 3.4
Figueraswi/o [56] 2000 35 85 NR 6.7NR NR NR 51% 60% 65 7.0
De Carliswi/o [57] 2001 131 91 NR NR 4.590-d 1890-d 38% 65% 62 7.0
ShabahangNR [58] 2002 44 65 NR NR 7.0NR 7.0NR 57%
3-YS
66%
3-YS NR NR
Bigourdanwi [59] 2003 20 17 3030-d 4730-d 5.030-d 030-d 36% 71% 30 18
PierieNR [60] 2005 81 33∗∗∗ NR NR 2030-d 9.030-d 10% 19% NR NR
Margaritwi [61] 2005 37 36 NR NR 2.730-d 5.630-d 78% 50% 59 11
Poonwi [62] 2007 204 43 3530-d 4430-d 3.4H 0H 68% 81% NR NR
Cillowi/o [63] 2007 131 40 NR NR 5.390-d 7.590-d 31% 63% 53 5.0
Del Gaudiowi [22] 2008 80 293 NR 79NR 0NR 5.0NR 66% 58% 59 46
Bellavancewi [64] 2008 245 134 4930-d 6530-d 1.630-d 1.530-d 46% 66% 50 14
Sotiropoulowi/o
[65] 2009 61 60 3830-d 3830-d 2330-d 8.030-d 23% 59% NR NR
Zhouwi [66] 2010 1018 89 NR NR 0.69NR 4.5NR 70% 89% NR NR
Abbreviations: RSX: resection; LT: liver transplantation; YS: year-survival; Mb: morbidity; MT: mortality; Rec: recurrence.
∗RSX and LT combined.
∗∗Cirrhotic and noncirrhotic livers combined.
∗∗∗33 wait-list patients (22 transplanted patients).
wiAll patients within Milan criteria.
wi/oSome patients within and some outside of Milan criteria.
NRMilan criteria not reported.
HHospital mortality (during same admission for same treatment).
occur from inappropriate stratiﬁcation based on stage of
disease. Staging of HCC is in fact plagued by an inordinate
number of staging systems. At the time of the recent
American Hepato-Pancreato-Biliary Association/American
Joint Commission on Cancer (AHPBA/AJCC) Consensus
Conference on Multidisciplinary Treatment of HCC staging
[7], there were 18 diﬀerent staging or scoring systems—
or versions thereof—in use around the world. A major
reason that HCC staging is diﬃcult is that, to a greater
extent in HCC compared with other cancers, prognosis after
surgical treatment of HCC depends not only on tumor
factors, such as size, number, and invasiveness (as are used
in AJCC staging), but also on factors related to patient
comorbidities,performancestatus,andquality-of-lifescores,
factors related to liver disease, factors related to etiology
of disease (e.g., alcohol versus hepatitis B versus hepatitis
C), and interactions between these groups of factors [7].
Whatever the reason—selection bias or a true ﬁnding—
the many available data suggest that the rates of long-term
survival and recurrence after transplantation are superior to
those observed following resection (Table 1).
In the early history of liver transplantation from the
1960s through the 1980s, transplantation was considered
to be indicated for primary liver tumors not resectable
by subtotal techniques [8–10]. However, recurrence rates
as high as 82% [10] and single-digit 5-year survival rates
[9] were disappointing. Subsequently, the observation [10–
12] that small HCC identiﬁed on pathologic evaluationInternational Journal of Hepatology 3
of explanted livers transplanted for other indications were
associated with low recurrence rates and long-term survival
led to the development of the above-mentioned Milan
criteria. Patients meeting these criteria in the original study
by Mazzaferro et al. had overall and recurrence-free 4-
years survival rates of 85% and 92% percent, respectively,
following liver transplantation [6]. These results have since
been corroborated in subsequent series published in the
2000s, with recurrence rates as low as 2% and 5-year survival
rates as high as 89% following liver transplantation for HCC
(Table 1).
4. Advantagesof Resection
4.1. Easier. Unfortunately, the high 5-year survival rates and
the low recurrence rates possible following liver transplan-
tation are available only to those patients waiting for a
graft who actually get one, whereas resection is more easily
and immediately available to all acceptable-risk patients. In
fact, the national median waiting times based on Organ
Procurement and Transplantation Network (OPTN) data as
ofDecember2010 rangefrom140daysforAmericanIndians
to 651 days for Hispanics [13], during which time patients
may drop out because of tumor or comorbid progression,
death, or other reasons. Depending on the time period, type
of analysis, and dropout criteria [14], the 1-year dropout
rate for patients with HCC awaiting liver transplantation
ranges from 12% to 38% [14–18]. When these dropouts
were considered in one of the ﬁrst intention-to-treat analyses
[19], the 2-year survival decreased signiﬁcantly from 84%
to 54%. Although subsequent intention-to-treat studies
accounting for dropouts have reported good 4-year survival
rates of approximately 60% following transplantation for
HCC [17, 18], other factors are not accounted for, such as
socioeconomic barriers that may prevent many patients ever
from being listed for transplantation. Resection, by contrast,
is available more easily, widely, and immediately to all
patients who can tolerate the operation. Not only is resection
a modality that is easier for patients to obtain, but it is
easier for surgeons to perform, since it almost never requires
venovenous bypass and does not require transplantation
fellowship training, which some but not all hepatobiliary
fellowships include. Resection, however, should not neces-
sarily be viewed as a mutually exclusive modality but rather
a complementary one, since its easy availability makes it
eﬀective not only in achieving long-term survival, but also
eﬀective for use as both a selection tool for transplantation,
and a bridge to transplantation, as discussed below.
4.2. Eﬀective. Given the absence of randomized controlled
trials comparing resection and transplantation, estimates of
their relative eﬀectiveness must at least be based on similar
patient populations to avoid selection bias. To that end,
several groups have studied transplantation-eligible patients,
that is, patients meeting the Milan criteria for transplanta-
tion, who underwent resection, not transplantation. Such
transplantation-eligible patients undergoing resection had
5-year survival rates of 70% at two large hepatobiliary
centers [20, 21] ,ar a t ec o m p a r a b l ew i t hs o m eo ft h e
best reported following liver transplantation (Table 1). In a
morerecentintention-to-treatanalysisof80transplantation-
eligible HCC patients who underwent resection compared
to 293 patients listed for transplantation, 5-year survival
was similar (66% and 58%, resp.) [22]. This is consistent
with the observation in a 2009 review of nearly 60 series
of resection and/or transplantation that the weighted mean
of reported 5-year survival rates is similar for resection and
transplantation: 48% and 52%, respectively [23].
Not only is resection eﬀective at producing a 5-year
survivalcomparabletothatoftransplantation,butincasesof
recurrence—which is uniformly higher following resection
compared with transplantation (Table 1)—transplantation
remains an option. This strategy of salvage liver trans-
plantation (SLT) has the advantage of limiting the impact
on the available pool of donors since the majority of
transplantation-eligible patients undergoing resection with-
out recurrence would not draw from this valuable and
limited resource of liver grafts.
Salvage transplantation was formally proposed ﬁrst in
1998byLlovetetal.[24],althoughseveralotherauthorswere
also studying this strategy around the same time [25–27].
Two simultaneously published articles in Annals of Surgery,
by Adam et al. [28] and Belghiti el al. [29], popularized the
approach in 2003, reporting disparate conclusions. Adam et
al. compared 17 patients who underwent SLT for recurrence
of HCC after resection with 195 patients following primary
liver transplantation (PLT) and found signiﬁcantly higher
mortality (23.5%), shorter survival, and more recurrence
in SLT patients compared to PLT [28]. Belghiti et al., by
contrast, included an intention-to-treat analysis and found
similar rates of complications, 5-year survival, and recur-
rence [29]. These latter results of Belghiti et al. have more
recently been corroborated by other groups. Del Gaudio
et al. reviewed the results of 227 cirrhotic patients with
transplantation-eligible HCC: 80 who underwent liver resec-
tion and 147 liver transplantation [22]. Among the liver-
resection patients, 49% recurred and of those who recurred,
69% were within the Milan criteria for transplantation, of
whom 10 underwent SLT. Compared with patients who
underwentprimarytransplantation,SLTpatientshadsimilar
rates of complications, 5-year survival, and recurrence [22].
Cherqui et al. studied 67 transplantation-eligible patients
who underwent resection and found that of 36 (54%)
patientswitharecurrence,16(44%)whounderwentSLThad
a 5-year survival rate of 70% [30].
De principe SLT is another strategy to minimize use of
scarcelivergraftsbyusingresectionasatooltoselectpatients
who, based on pathologic evaluation of the specimen,
have risk factors for recurrence (e.g., microscopic vascular
invasion, the presence of previously unrecognized small
satellite nodules). The Barcelona Clinic Liver Cancer group
has employed this strategy, ﬁnding it to be an eﬀective way to
improvetheoutcomeofresectedpatients[31].Of17patients
who were candidates for either resection or transplantation,
but who underwent resection, 8 were deemed high-risk
and therefore oﬀered immediate transplantation. Of 6 who
agreed to de prinicipe SLT, 5 were transplanted and although
4 of these 5 had no pretransplantation evidence of HCC,4 International Journal of Hepatology
4 indeed were found to harbor unrecognized HCC in the
explanted liver but were free of disease at a median follow
up of 45 months [31].
The use of resection as an eﬀective tool to select patients
for de prinicipe SLT was corroborated by Scatton et al. who
studied 93 patients who underwent curative-intent surgery
for HCC, primary resection in 20 (all 20 of whom had well-
compensated cirrhosis with a Model for End-Stage Liver
Disease score of 8) and primary transplantation in 73 [32].
Six of the 20 resection patients underwent de principe SLT
and 14 underwent SLT for actual recurrence. Not all 20
were within the Milan criteria at resection: Twelve (9 SLT
and 3 de principe)w e r ew i t h i na n d8( 5S L Ta n d3de
principe) were beyond the Milan criteria. The 20 patients
undergoing resection followed by transplantation and the
73 undergoing PLT had 5-year survival rates (55% and
66%, resp.) that were statistically similar [32]. This study
supports the notion that pathologic examination of resected
specimens allows determination of which patients beneﬁt
most from an eventual transplantation, and allows the
opportunity to perform it preemptively.
4.3. Safer. Not only is liver resection easier and as eﬀective
as primary transplantation, it is also likely safer. Although
this claim is made with the understanding that there are no
randomized controlled trials to support it, it is intuitively
true, given that all transplantations are major and complex
operations, even when done for small tumors. A liver
resection for a small tumor, in a liver with well-compensated
cirrhosis, however, is in general a lower-risk procedure, and
can sometimes even be performed laparoscopically. In fact,
a series of 163 liver resections for HCC (74% on cirrhosis)
performed at 3 large European centers recently reported
median operative time of 180min, blood loss of 250mL, and
tumor size 3.6cm, with a mean length of stay of 7 days [33].
A recent review of nearly 60 series of either transplantation,
resection, or direct comparisons of the two modalities in
the treatment of early HCC found that the weighted means
of postoperative morbidity rates was nearly identical (44%
for resection and 45% for transplantation), but mortality
following transplantation was 60% higher than following
resection (8% and 5%, resp.) [23].
While both resection and transplantation may be per-
formed safely, resection has the additional advantage of
delaying need for and risks associated with immunosup-
pression. These risks include toxicities (especially nephro-
toxicity), infectious complications, and posttransplanta-
tion de novo neoplasms, among others. Nephrotoxicity is
common after liver transplantation and adversely aﬀects
graft and patient survival [34]. Immunosuppression-related
posttransplantation infection is a signiﬁcant problem that
is entirely avoided with resection. In a series of 1000 liver
transplantations treated with tacrolilmus immunosuppres-
sion, posttransplantation infection was the most common
cause of death (34% of 360 deaths) [35]. In cases of HCV-
related HCC, reinfection of a new liver graft following
transplantation is universal and serum HCV levels have been
shown to increase 4- to 100-fold during treatment for acute
rejection [36]. Posttransplantation neoplasms occur at a rate
several-fold higher than age- and sex-matched individuals
[37], and include skin cancers and lymphoma (up to 10-
foldrisk)[37–40],myelodysplasticsyndrome[41],andother
extrahepatic cancers, such as those of the head and neck,
lung, and gastrointestinal tract [42].
4.4. Simpler. In addition to being safer, easier, and compa-
rably eﬀective relative to transplantation, resection has the
advantage of simpler preoperative and postoperative man-
agement. Any patient being evaluated for either modality
requires extensive workup regarding HCC and comorbid
factors, but transplantation requires in addition an extensive
preoperative process that includes myriad wait-list issues,
psychosocialevaluationofrecipientsandlivedonors,andthe
universal emergent nature of the operations.
Bryce et al. [43] have studied the impact of sociode-
mographic factors on access to transplantation services and
identiﬁed six stages that a patient must pass through prior
to transplantation: disease occurrence, disease progression,
disease diagnosis, referral for transplantation, listing for
transplantation, and ﬁnally organ transplantation. Reasons
preventing patients from completing all of these stages are
numerous and include medical unsuitability for a trans-
plantation, refusal of treatment, disparities/bias, and death.
Using Pennsylvania state databases to collect sociodemo-
graphic and socioeconomic information, they linked data
to records from ﬁve centers responsible for 95% of liver
transplantations in Pennsylvania, and found that patients
were signiﬁcantly less likely to undergo evaluation, wait-
listing, and transplantation if they were women, African
American, or lacked commercial insurance [43]. Further-
more, these diﬀerences were greater during the early stages
of the preoperative process (referral and listing) than for
the ﬁnal transplantation stage, where national oversight and
review occur [43].
Postoperative management is similarly complex and
requires a higher level of dedication, compliance, and
investment of time, energy, and attention on the part of
the patient than is possible for many patients, especially
those of lower socioeconomic status. Noncompliance with
immunosuppressive regimens and follow-up schedules has
obvious risk for graft rejection and systemic toxicity and
is more common in patients of low socioeconomic status
[44]. Furthermore, for reasons that are not well deﬁned, low-
socioeconomic patients may also have worse survival follow-
ing transplantation for HCC. In a study of 4735 patients
identiﬁed in the OPTN database, although the survival of
all patients with HCC improved over time regardless of
racial, ethnic, and income groups, African American and
low-income individuals had signiﬁcantly poorer long-term
survival compared to other socioeconomic groups [45].
5. Conclusion
Although liver transplantation provides the best recurrence-
free survival and the best chance for a cure of HCC on
well-compensated cirrhosis, due to the complete removal of
all hepatic HCC disease and all oncogenic cirrhotic liver,
the current (and likely future) shortage of available grafts,International Journal of Hepatology 5
and the increased risks and complexities associated with the
pre-, intra-, and postoperative course of liver transplantation
counterbalance this advantage of transplantation. Further-
more, in cases of recurrence (or high risk thereof)—the one
clear disadvantage of resection—transplantation remains a
safe option. Taken together, these arguments suggest that
resection is easier, safer, simpler, and as eﬀective compared
with transplantation and therefore is the optimal ﬁrst choice
for patients with early HCC on well-compensated cirrhosis.
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